Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open Label, Phase 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

NCT02006030 is registered in ClinicalTrials.gov with Polaris Group as lead sponsor.

NCT NCT02006030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02006030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open Label, Phase 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
Lead sponsor
Polaris Group
Phase
Phase 2
Overall status
Completed
Start date
October 15, 2014
Completion date
November 1, 2017
Enrollment
30 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable hepatocellular carcinoma